Residual risk of liver disease after hepatitis C virus eradication
- 1 April 2021
- journal article
- research article
- Published by Elsevier in Journal of Hepatology
- Vol. 74 (4) , 952-963
Abstract
No abstract availableKeywords
Funding Information
- AbbVie
- Merck
- Gilead Sciences
This publication has 76 references indexed in Scilit:
- Non-invasive monitoring of liver disease regression in patients with advanced chronic liver disease after sustained virologic response to INF-free therapiesJournal of Hepatology, 2020
- Predictors of hepatocellular carcinoma recurrence associated with the use of direct‐acting antiviral agent therapy for hepatitis C virus after curative treatment: A prospective multicenter cohort studyCancer Medicine, 2019
- Autoimmune hepatitis in patients with chronic HBV and HCV infections: patterns of clinical characteristics, disease progression and outcomeAnnals of Hepatology, 2014
- Evaluation of liver disease progression in the German hepatitis C virus (1b)-contaminated anti-D cohort at 35 years after infectionHepatology, 2014
- Association Between Sustained Virological Response and All-Cause Mortality Among Patients With Chronic Hepatitis C and Advanced Hepatic FibrosisJAMA, 2012
- The interaction of metabolic factors with HCV infection: Does it matter?Journal of Hepatology, 2012
- Excess liver-related morbidity of chronic hepatitis C patients, who achieve a sustained viral response, and are discharged from careHepatology, 2011
- Sustained virological response to interferon-α is associated with improved outcome in HCV-related cirrhosis: A retrospective studyHepatology, 2007
- Latent autoimmune hepatitis triggered during interferon therapy in patients with chronic hepatitis CGastroenterology, 1995
- Acute exacerbation of liver disease during interferon alfa therapy for chronic hepatitis CGastroenterology, 1992